Prognostic Parameters of Palbociclib in HR+/HER2- Advanced Breast Cancer: A Narrative Review

Recent studies have demonstrated that the combination of Cyclin-Dependent Kinase 4/6 Inhibitor (CDK4/6i) and endocrine therapy (ET) is more effective than ET alone and significantly improves progression-free survival (PFS) and overall survival (OS) in patients with hormone receptor-positive (HR+)/hu...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Wei, Wu, Jiayi, Chen, Keyu, Wang, Xiaojia, Shao, Xiying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10192799/
https://www.ncbi.nlm.nih.gov/pubmed/37186799
http://dx.doi.org/10.1177/15330338231173504
_version_ 1785043704462966784
author Wang, Wei
Wu, Jiayi
Chen, Keyu
Wang, Xiaojia
Shao, Xiying
author_facet Wang, Wei
Wu, Jiayi
Chen, Keyu
Wang, Xiaojia
Shao, Xiying
author_sort Wang, Wei
collection PubMed
description Recent studies have demonstrated that the combination of Cyclin-Dependent Kinase 4/6 Inhibitor (CDK4/6i) and endocrine therapy (ET) is more effective than ET alone and significantly improves progression-free survival (PFS) and overall survival (OS) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor-2 negative (HER2-) breast cancer (BC). Palbociclib is the first CDK4/6i approved for use, and its clinical advantages have been shown. However, 30% of patients will continue to develop secondary drug resistance. Therefore, exploring the parameters that can predict the efficacy of Palbociclib and developing a clinical prediction model is essential for evaluating the prognosis of patients.
format Online
Article
Text
id pubmed-10192799
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-101927992023-05-19 Prognostic Parameters of Palbociclib in HR+/HER2- Advanced Breast Cancer: A Narrative Review Wang, Wei Wu, Jiayi Chen, Keyu Wang, Xiaojia Shao, Xiying Technol Cancer Res Treat Review Recent studies have demonstrated that the combination of Cyclin-Dependent Kinase 4/6 Inhibitor (CDK4/6i) and endocrine therapy (ET) is more effective than ET alone and significantly improves progression-free survival (PFS) and overall survival (OS) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor-2 negative (HER2-) breast cancer (BC). Palbociclib is the first CDK4/6i approved for use, and its clinical advantages have been shown. However, 30% of patients will continue to develop secondary drug resistance. Therefore, exploring the parameters that can predict the efficacy of Palbociclib and developing a clinical prediction model is essential for evaluating the prognosis of patients. SAGE Publications 2023-05-15 /pmc/articles/PMC10192799/ /pubmed/37186799 http://dx.doi.org/10.1177/15330338231173504 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Wang, Wei
Wu, Jiayi
Chen, Keyu
Wang, Xiaojia
Shao, Xiying
Prognostic Parameters of Palbociclib in HR+/HER2- Advanced Breast Cancer: A Narrative Review
title Prognostic Parameters of Palbociclib in HR+/HER2- Advanced Breast Cancer: A Narrative Review
title_full Prognostic Parameters of Palbociclib in HR+/HER2- Advanced Breast Cancer: A Narrative Review
title_fullStr Prognostic Parameters of Palbociclib in HR+/HER2- Advanced Breast Cancer: A Narrative Review
title_full_unstemmed Prognostic Parameters of Palbociclib in HR+/HER2- Advanced Breast Cancer: A Narrative Review
title_short Prognostic Parameters of Palbociclib in HR+/HER2- Advanced Breast Cancer: A Narrative Review
title_sort prognostic parameters of palbociclib in hr+/her2- advanced breast cancer: a narrative review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10192799/
https://www.ncbi.nlm.nih.gov/pubmed/37186799
http://dx.doi.org/10.1177/15330338231173504
work_keys_str_mv AT wangwei prognosticparametersofpalbociclibinhrher2advancedbreastcanceranarrativereview
AT wujiayi prognosticparametersofpalbociclibinhrher2advancedbreastcanceranarrativereview
AT chenkeyu prognosticparametersofpalbociclibinhrher2advancedbreastcanceranarrativereview
AT wangxiaojia prognosticparametersofpalbociclibinhrher2advancedbreastcanceranarrativereview
AT shaoxiying prognosticparametersofpalbociclibinhrher2advancedbreastcanceranarrativereview

Ejemplares similares